| Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised … B Burtness, KJ Harrington, R Greil, D Soulières, M Tahara, G de Castro, ... The Lancet 394 (10212), 1915-1928, 2019 | 2244 | 2019 |
| Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial H Mehanna, M Robinson, A Hartley, A Kong, B Foran, T Fulton-Lieuw, ... The Lancet 393 (10166), 51-60, 2019 | 903 | 2019 |
| Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 … W Taal, HM Oosterkamp, AME Walenkamp, HJ Dubbink, LV Beerepoot, ... The lancet oncology 15 (9), 943-953, 2014 | 835 | 2014 |
| The additional value of chemotherapy to radiotherapy in locally advanced nasopharyngeal carcinoma: a meta-analysis of the published literature JA Langendijk, CR Leemans, J Buter, J Berkhof, BJ Slotman Journal of clinical oncology 22 (22), 4604-4612, 2004 | 620 | 2004 |
| Oral metastases: report of 24 cases RIF Van der Waal, J Buter, I Van der Waal British Journal of Oral and Maxillofacial Surgery 41 (1), 3-6, 2003 | 415 | 2003 |
| A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus BM Tijink, J Buter, R De Bree, G Giaccone, MS Lang, A Staab, ... Clinical Cancer Research 12 (20), 6064-6072, 2006 | 342 | 2006 |
| Treatment of anthracycline extravasation with Savene (dexrazoxane): results from two prospective clinical multicentre studies HT Mouridsen, SW Langer, J Buter, H Eidtmann, G Rosti, M De Wit, ... Annals of Oncology 18 (3), 546-550, 2007 | 230 | 2007 |
| Phase II study of subcutaneous interleukin-2 in unselected patients with advanced renal cell cancer on an outpatient basis DT Sleijfer, RA Janssen, J Buter, EG De Vries, PH Willemse, NH Mulder J Clin Oncol 10 (7), 1119-1123, 1992 | 224 | 1992 |
| Phase II study of 3-AP Triapine in patients with recurrent or metastatic head and neck squamous cell carcinoma CM Nutting, CML Van Herpen, AB Miah, SA Bhide, JP Machiels, J Buter, ... Annals of oncology 20 (7), 1275-1279, 2009 | 192 | 2009 |
| Malignant peripheral nerve sheath tumors in patients with and without neurofibromatosis PF Doorn, WM Molenaar, J Buter, HJ Hoekstra European Journal of Surgical Oncology (EJSO) 21 (1), 78-82, 1995 | 177 | 1995 |
| Recombinant human interleukin-6 induces a rapid and reversible anemia in cancer patients J Nieken, NH Mulder, J Buter, E Vellenga, PC Limburg, DA Piers, ... | 175 | 1995 |
| 18F-2-Fluoro-2-Deoxy-d-Glucose Positron Emission Tomography in Staging of Locally Advanced Breast Cancer JJM Van Der Hoeven, NC Krak, OS Hoekstra, EFI Comans, RPA Boom, ... Journal of clinical oncology 22 (7), 1253-1259, 2004 | 161 | 2004 |
| Intra‐arterial versus intravenous chemoradiation for advanced head and neck cancer: Results of a randomized phase 3 trial CRN Rasch, M Hauptmann, J Schornagel, O Wijers, J Buter, T Gregor, ... Cancer 116 (9), 2159-2165, 2010 | 155 | 2010 |
| Tumor volume as prognostic factor in chemoradiation for advanced head and neck cancer JL Knegjens, M Hauptmann, FA Pameijer, AJ Balm, FJ Hoebers, ... Head & neck 33 (3), 375-382, 2011 | 126 | 2011 |
| Salvage laryngectomy: oncological and functional outcome L Van der Putten, R De Bree, DJ Kuik, DHF Rietveld, J Buter, ... Oral oncology 47 (4), 296-301, 2011 | 122 | 2011 |
| Androgen deprivation therapy for androgen receptor‐positive advanced salivary duct carcinoma: a nationwide case series of 35 patients in The Netherlands E Boon, W van Boxtel, J Buter, RJ Baatenburg de Jong, RJJ van Es, M Bel, ... Head & neck 40 (3), 605-613, 2018 | 115 | 2018 |
| The course of health-related quality of life in head and neck cancer patients treated with chemoradiation: a prospective cohort study IM Verdonck-de Leeuw, LM Buffart, MW Heymans, DH Rietveld, ... Radiotherapy and Oncology 110 (3), 422-428, 2014 | 115 | 2014 |
| Identification of patients with recurrent glioblastoma who may benefit from combined bevacizumab and CCNU therapy: a report from the BELOB trial L Erdem-Eraslan, MJ van den Bent, Y Hoogstrate, H Naz-Khan, A Stubbs, ... Cancer research 76 (3), 525-534, 2016 | 109 | 2016 |
| Prevalence of swallowing and speech problems in daily life after chemoradiation for head and neck cancer based on cut-off scores of the patient-reported outcome measures SWAL … RN Rinkel, IM Verdonck-de Leeuw, P Doornaert, J Buter, R de Bree, ... European Archives of Oto-Rhino-Laryngology 273, 1849-1855, 2016 | 102 | 2016 |
| Cognitive functioning in glioblastoma patients during radiotherapy and temozolomide treatment: initial findings K Hilverda, I Bosma, JJ Heimans, TJ Postma, W Peter Vandertop, ... Journal of neuro-oncology 97, 89-94, 2010 | 100 | 2010 |
